Lord Abbett & CO. LLC reduced its stake in shares of Evolus, Inc. (NASDAQ:EOLS - Free Report) by 50.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 497,849 shares of the company's stock after selling 497,600 shares during the period. Lord Abbett & CO. LLC owned approximately 0.79% of Evolus worth $5,496,000 at the end of the most recent quarter.
A number of other large investors have also recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. raised its position in Evolus by 10.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 13,426 shares of the company's stock worth $148,000 after buying an additional 1,291 shares during the last quarter. Rhumbline Advisers raised its holdings in shares of Evolus by 2.2% during the fourth quarter. Rhumbline Advisers now owns 80,149 shares of the company's stock worth $885,000 after purchasing an additional 1,762 shares during the last quarter. Tradition Wealth Management LLC raised its holdings in shares of Evolus by 18.2% during the fourth quarter. Tradition Wealth Management LLC now owns 13,000 shares of the company's stock worth $144,000 after purchasing an additional 2,000 shares during the last quarter. MetLife Investment Management LLC lifted its position in Evolus by 6.3% during the fourth quarter. MetLife Investment Management LLC now owns 34,272 shares of the company's stock valued at $378,000 after purchasing an additional 2,044 shares during the period. Finally, Teacher Retirement System of Texas boosted its holdings in Evolus by 19.5% in the fourth quarter. Teacher Retirement System of Texas now owns 14,084 shares of the company's stock valued at $155,000 after purchasing an additional 2,302 shares during the last quarter. 90.69% of the stock is owned by hedge funds and other institutional investors.
Evolus Price Performance
NASDAQ EOLS traded up $0.28 during trading hours on Friday, reaching $12.08. The company's stock had a trading volume of 957,476 shares, compared to its average volume of 664,883. The firm has a market capitalization of $778.81 million, a price-to-earnings ratio of -13.27 and a beta of 1.11. The company's 50-day moving average is $11.98 and its two-hundred day moving average is $12.74. The company has a debt-to-equity ratio of 20.58, a current ratio of 2.47 and a quick ratio of 2.23. Evolus, Inc. has a 1-year low of $8.67 and a 1-year high of $17.82.
Insider Activity
In other news, insider Rui Avelar sold 27,904 shares of the business's stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $13.26, for a total transaction of $370,007.04. Following the completion of the sale, the insider now owns 362,467 shares of the company's stock, valued at $4,806,312.42. The trade was a 7.15 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider David Moatazedi sold 6,251 shares of the firm's stock in a transaction dated Thursday, March 27th. The shares were sold at an average price of $12.40, for a total transaction of $77,512.40. Following the completion of the transaction, the insider now directly owns 508,619 shares in the company, valued at $6,306,875.60. This represents a 1.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 60,575 shares of company stock worth $794,369 over the last three months. 6.10% of the stock is currently owned by corporate insiders.
Wall Street Analysts Forecast Growth
EOLS has been the subject of several analyst reports. BTIG Research began coverage on Evolus in a report on Thursday, April 17th. They issued a "buy" rating and a $21.00 price objective for the company. HC Wainwright reissued a "buy" rating and issued a $27.00 price target on shares of Evolus in a report on Thursday, April 10th. Barclays raised their price objective on shares of Evolus from $22.00 to $25.00 and gave the stock an "overweight" rating in a research note on Wednesday, March 5th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $22.00 target price on shares of Evolus in a research note on Wednesday, April 9th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $23.75.
Check Out Our Latest Analysis on Evolus
About Evolus
(
Free Report)
Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.
Read More
Before you consider Evolus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evolus wasn't on the list.
While Evolus currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
